Alpha 2.0
Login Register
» Authors » Rama Kandasamy

Rama Kandasamy

Explore the profile of Rama Kandasamy including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 26
Citations 291
Followers 0
Related Specialties
Infectious Diseases
Microbiology
Pediatrics
Top 10 Co-Authors
Andrew J Pollard
Merryn Voysey
Stephen Thorson
Shrijana Shrestha
Meeru Gurung
Dominic F Kelly
David R Murdoch
Sarah Kelly
Jason Hinds
Imran Ansari
Published In
J Infect Dis
Pediatr Infect Dis J
Vaccine
Lancet Infect Dis
J Infect
Affiliations
Soon will be listed here.
Recent Articles
11.
A lineage usually associated with pneumococcal conjugate vaccine (PCV) serotypes is the most common cause of serotype 35B invasive disease in South Africa, following routine use of PCV
Ndlangisa K, du Plessis M, Lo S, de Gouveia L, Chaguza C, Antonio M, et al.
Microb Genom . 2022 Apr; 8(4). PMID: 35384831
Pneumococcal serotype 35B is an important non-conjugate vaccine (non-PCV) serotype. Its continued emergence, post-PCV7 in the USA, was associated with expansion of a pre-existing 35B clone (clonal complex [CC] 558)...
12.
Childhood Invasive Bacterial Disease in Kathmandu, Nepal (2005-2013)
Carter M, Gurung M, Pokhrel B, Bijukchhe S, Karmacharya S, Khadka B, et al.
Pediatr Infect Dis J . 2021 Dec; 41(3):192-198. PMID: 34955523
Background: Invasive bacterial disease (IBD; including pneumonia, meningitis, sepsis) is a major cause of morbidity and mortality in children in low-income countries. Methods: We analyzed data from a surveillance study...
13.
Persistence of Immunity Following 2-Dose Priming with a 10-Valent Pneumococcal Conjugate Vaccine at 6 and 10 Weeks or 6 and 14 Weeks of Age in Nepalese Toddlers
Gurung M, Bijukchhe S, Hariri P, Voysey M, Kandasamy R, Thorson S, et al.
Pediatr Infect Dis J . 2021 Jul; 40(10):937-943. PMID: 34292271
Background: The pneumococcal conjugate vaccine has had a substantial impact on invasive pneumococcal disease. Previously, we compared immunity following vaccination with the 10-valent pneumococcal conjugate vaccine (PCV10) administered at 2...
14.
Upper airways colonisation of Streptococcus pneumoniae in adults aged 60 years and older: A systematic review of prevalence and individual participant data meta-analysis of risk factors
Smith E, Wheeler I, Adler H, Ferreira D, Sa-Leao R, Abdullahi O, et al.
J Infect . 2020 Jun; 81(4):540-548. PMID: 32562794
Background: Colonisation with Streptococcus pneumoniae can lead to invasive pneumococcal disease and pneumonia. Pneumococcal acquisition and prevalence of colonisation are high in children. In older adults, a population susceptible to...
15.
Assessment of an Antibody-in-Lymphocyte Supernatant Assay for the Etiological Diagnosis of Pneumococcal Pneumonia in Children
Carter M, Gurung P, Jones C, Rajkarnikar S, Kandasamy R, Gurung M, et al.
Front Cell Infect Microbiol . 2020 Feb; 9:459. PMID: 32039044
New diagnostic tests for the etiology of childhood pneumonia are needed. We evaluated the antibody-in-lymphocyte supernatant (ALS) assay to detect immunoglobulin (Ig) G secretion from peripheral blood mononuclear cell (PBMC)...
16.
A mosaic tetracycline resistance gene tet(S/M) detected in an MDR pneumococcal CC230 lineage that underwent capsular switching in South Africa
Lo S, Gladstone R, van Tonder A, du Plessis M, Cornick J, Hawkins P, et al.
J Antimicrob Chemother . 2019 Dec; 75(3):512-520. PMID: 31789384
Objectives: We reported tet(S/M) in Streptococcus pneumoniae and investigated its temporal spread in relation to nationwide clinical interventions. Methods: We whole-genome sequenced 12 254 pneumococcal isolates from 29 countries on...
17.
Persistent Circulation of Vaccine Serotypes and Serotype Replacement After 5 Years of Infant Immunization With 13-Valent Pneumococcal Conjugate Vaccine in the United Kingdom
Kandasamy R, Voysey M, Collins S, Berbers G, Robinson H, Noel I, et al.
J Infect Dis . 2019 Apr; 221(8):1361-1370. PMID: 31004136
Background: Following programmatic introduction of the 13-valent pneumococcal conjugate vaccine (PCV13), there is residual carriage and disease due to PCV13-covered serotypes. Methods: PCV13-immunized children aged 13-48 months, N = 988,...
18.
Comparison of two schedules of two-dose priming with the ten-valent pneumococcal conjugate vaccine in Nepalese children: an open-label, randomised non-inferiority controlled trial
Kandasamy R, Gurung M, Thorson S, Yu L, Galal U, Voysey M, et al.
Lancet Infect Dis . 2019 Jan; 19(2):156-164. PMID: 30635252
Background: Nepalese infants receive ten-valent pneumococcal conjugate vaccine (PCV10) with a 1 month interval between priming doses for programmatic reasons. We aimed to investigate whether immune responses to PCV10 serotypes...
19.
The relative invasive disease potential of Streptococcus pneumoniae among children after PCV introduction: A systematic review and meta-analysis
Balsells E, Dagan R, Yildirim I, Gounder P, Steens A, Munoz-Almagro C, et al.
J Infect . 2018 Jul; 77(5):368-378. PMID: 29964140
Objectives: Burden of pneumococcal disease depends on the prevalence and invasive disease potential of serotypes. We aimed to estimate the invasive disease potential of serotypes in children under 5 years...
20.
Global Distribution of Invasive Serotype 35D Streptococcus pneumoniae Isolates following Introduction of 13-Valent Pneumococcal Conjugate Vaccine
Lo S, Gladstone R, van Tonder A, Hawkins P, Kwambana-Adams B, Cornick J, et al.
J Clin Microbiol . 2018 May; 56(7). PMID: 29720431
A newly recognized pneumococcal serotype, 35D, which differs from the 35B polysaccharide in structure and serology by not binding to factor serum 35a, was recently reported. The genetic basis for...